小剂量罗红霉素对支气管扩张症NF-κB通路及气道炎症的影响以及临床疗效研究

目的观察小剂量罗红霉素对支气管扩张症患者NF-κB通路及气道炎症的影响。方法 92例支气管扩张症患者分为对照组和小剂量罗红霉素治疗观察组,每组46例。p65、IL-6和TNF-α蛋白的表达检测使用ELISA法。结果治疗后观察组p65、IL-6和TNF-α蛋白表达显著减低(P0.05),但对照组无显著性变化(P0.05)。治疗后观察组对生活质量评分、呼吸困难评分和痰量的减低作用,以及对FEV1%和FEV1/FVC的升高作用显著优于对照组(P0.05)。治疗期间观察组急性加重1.54±0.28次,显著低于对照组的2.12±0.46次(P0.05)。观察组临床治疗有效率为84.8%(39/46),显著高于对照组的71.7%(33/46)(P0.05)。观察组临床治疗不良反应率为13.0%(6/46),对照组临床治疗不良反应率为10.9%(5/46),两组之间无显著性差异(P0.05)。结论小剂量罗红霉素可以抑制支气管扩张症患者NF-κB通路,减轻气道高炎症反应,改善患者临床症状,提高生活质量和肺功能,疗效显著,使用安全。

Effect of low dose roxithromycin on NF-κB pathway and airway inflammation in patients with bronchiectasis and its clinical efficacy

Objective To detect the effect of low dose roxithromycin on NF-κB pathway and airway inflam-mation in patients with bronchiectasis. Methods A total of 92 bronchiectasis patients were enrolled in this study, and they were randomly divided into the control group (n=46) and the low dose roxithromycin observation group (n=46). The expression of p65, IL-6 and TNF-α were detected by ELISA analysis. Results After treatment, p65, IL-6 and TNF-αdecreased in the observation group (P<0. 05) and didn’t change in the control group (P>0. 05). After treatment, life quality score, dyspnea score, and day and night sputum volume was lower in the observation group than in the control group (P<0. 05), and FEV1% and FEV1/FVC was higher in the observation group than in the control group ( P<0. 05 ) . The acute exacerbation frequency was 1. 54 ± 0. 28 times in the observation group, which was significantly lower than that of 2. 12 ± 0. 46 times in the control group (P<0. 05). The rate of clinic effect was 84. 8% (39/46) in the observation group, which was higher than 71. 7% (33/46) in the control group (P<0. 05). The incidence of adverse reaction was 13. 0% (6/46) in the observation group and 10. 9% (5/46) in the control group. There was no significant difference between the two groups (P>0. 05). Conclusion Low dose rox-ithromycins can inhibit NF-κB pathway and airway local inflammatory response in patients with bronchiectasis, which can improve clinical symptoms, life quality, and lung function, with significantly clinical efficacy and safety.